Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss

Luke S. Tain, Heather Mortiboys, Ran N. Tao, Elena Ziviani, Oliver Bandmann, Alexander J. Whitworth

Research output: Contribution to journalArticlepeer-review

Abstract

Mutations in PINK1 and PARK2 cause autosomal recessive parkinsonism, a neurodegenerative disorder that is characterized by the loss of dopaminergic neurons. To discover potential therapeutic pathways, we identified factors that genetically interact with Drosophila park and Pink1. We found that overexpression of the translation inhibitor Thor (4E-BP) can suppress all of the pathologic phenotypes, including degeneration of dopaminergic neurons in Drosophila. 4E-BP is activated in vivo by the TOR inhibitor rapamycin, which could potently suppress pathology in Pink1 and park mutants. Rapamycin also ameliorated mitochondrial defects in cells from individuals with PARK2 mutations. Recently, 4E-BP was shown to be inhibited by the most common cause of parkinsonism, dominant mutations in LRRK2. We also found that loss of the Drosophila LRRK2 homolog activated 4E-BP and was also able to suppress Pink1 and park pathology. Thus, in conjunction with recent findings, our results suggest that pharmacologic stimulation of 4E-BP activity may represent a viable therapeutic approach for multiple forms of parkinsonism.

Original languageEnglish
Pages (from-to)1129-1135
Number of pages7
JournalNature Neuroscience
Volume12
Issue number9
DOIs
Publication statusPublished - Sep 2009

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss'. Together they form a unique fingerprint.

Cite this